title: Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
abstract: Parkinson's disease (PD) is the second most common neurodegenerative disease and is characterized by dopaminergic (DA) neuronal cell loss in the substantia nigra. Although the entire pathogenesis of PD is still unclear, both environmental and genetic factors contribute to neurodegeneration. Epidemiologic studies show that prevalence of PD is lower in smokers than in nonsmokers. Nicotine, a releaser of dopamine from DA neurons, is one of the candidates of antiparkinson agents in tobacco. To assess the protective effect of nicotine against rotenone-induced DA neuronal cell toxicity, we examined the neuroprotective effects of nicotine in rotenone-induced PD models in vivo and in vitro. We observed that simultaneous subcutaneous administration of nicotine inhibited both motor deficits and DA neuronal cell loss in the substantia nigra of rotenone-treated mice. Next, we analyzed the molecular mechanisms of DA neuroprotective effect of nicotine against rotenone-induced toxicity with primary DA neuronal culture. We found that DA neuroprotective effects of nicotine were inhibited by dihydro-beta-erythroidine (DHbetaE), alpha-bungarotoxin (alphaBuTx), and/or PI3K-Akt/PKB (protein serine/threonine kinase B) inhibitors, demonstrating that rotenone-toxicity on DA neurons are inhibited via activation of alpha4beta2 or alpha7 nAChRs-PI3K-Akt/PKB pathway or pathways. These results suggest that the rotenone mouse model may be useful for assessing candidate antiparkinson agents, and that nAChR (nicotinic acetylcholine receptor) stimulation can protect DA neurons against degeneration.
authors.affiliation: Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Takeuchi
authors.forename: Takashi
authors.initials: T
authors.lastname: Yanagida
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Inden
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Takata
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yamakawa
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Sawada
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Izumi
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kihara
authors.forename: Kengo
authors.initials: K
authors.lastname: Uemura
authors.forename: Haruhisa
authors.initials: H
authors.lastname: Inoue
authors.forename: Takashi
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Akinori
authors.initials: A
authors.lastname: Akaike
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Takahashi
authors.forename: Shun
authors.initials: S
authors.lastname: Shimohama
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D015153:Blotting, Western; D018678:Cholinergic Agents / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009474:Neurons / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009538:Nicotine / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology*; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000378:metabolism*; D012402:Rotenone / Q000633:toxicity; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D014475:Uncoupling Agents / Q000633:toxicity
chemical_list: D018678:Cholinergic Agents; D011978:Receptors, Nicotinic; D014475:Uncoupling Agents; D012402:Rotenone; D009538:Nicotine; D004298:Dopamine